genOway Société anonyme (ALGEN.PA)
EUR 3.92
(0.0%)
EUR 3.92
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.97 Million EUR | -28.64% |
| 2022 | 4.16 Million EUR | -20.19% |
| 2021 | 5.22 Million EUR | -35.11% |
| 2020 | 8.04 Million EUR | 63.22% |
| 2019 | 4.92 Million EUR | 204.84% |
| 2018 | 1.61 Million EUR | 899.88% |
| 2017 | -202.15 Thousand EUR | 92.32% |
| 2016 | -2.63 Million EUR | 30.29% |
| 2015 | -3.77 Million EUR | -4.63% |
| 2014 | -3.6 Million EUR | 20.54% |
| 2013 | -4.54 Million EUR | -14.21% |
| 2012 | -3.97 Million EUR | 34.92% |
| 2011 | -6.11 Million EUR | -9.86% |
| 2010 | -5.56 Million EUR | -21.77% |
| 2009 | -4.56 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 2.97 Million EUR | 0.0% |
| 2023 Q2 | 5.31 Million EUR | 0.0% |
| 2023 FY | 2.97 Million EUR | -28.64% |
| 2022 Q4 | 4.16 Million EUR | 0.0% |
| 2022 Q2 | 3.92 Million EUR | 0.0% |
| 2022 FY | 4.16 Million EUR | -20.19% |
| 2021 Q2 | 6.64 Million EUR | 0.0% |
| 2021 FY | 5.22 Million EUR | -35.11% |
| 2021 Q4 | 5.22 Million EUR | 0.0% |
| 2020 Q2 | 3.57 Million EUR | 0.0% |
| 2020 Q4 | 8.04 Million EUR | 0.0% |
| 2020 FY | 8.04 Million EUR | 63.22% |
| 2019 Q2 | 5.84 Million EUR | 0.0% |
| 2019 Q4 | 4.92 Million EUR | 0.0% |
| 2019 FY | 4.92 Million EUR | 204.84% |
| 2018 Q2 | 3.26 Million EUR | 0.0% |
| 2018 FY | 1.61 Million EUR | 899.88% |
| 2018 Q4 | 1.61 Million EUR | 0.0% |
| 2017 Q4 | -202.15 Thousand EUR | 0.0% |
| 2017 Q2 | 1.24 Million EUR | 0.0% |
| 2017 FY | -202.15 Thousand EUR | 92.32% |
| 2016 Q4 | -2.63 Million EUR | 0.0% |
| 2016 Q2 | -2.35 Million EUR | 0.0% |
| 2016 FY | -2.63 Million EUR | 30.29% |
| 2015 FY | -3.77 Million EUR | -4.63% |
| 2015 Q2 | -2.91 Million EUR | 0.0% |
| 2015 Q4 | -3.77 Million EUR | 0.0% |
| 2014 Q4 | -3.6 Million EUR | 0.0% |
| 2014 Q2 | -3.6 Million EUR | 0.0% |
| 2014 FY | -3.6 Million EUR | 20.54% |
| 2013 Q2 | -4.03 Million EUR | 0.0% |
| 2013 Q4 | -4.54 Million EUR | 0.0% |
| 2013 FY | -4.54 Million EUR | -14.21% |
| 2012 FY | -3.97 Million EUR | 34.92% |
| 2012 Q4 | -3.97 Million EUR | 0.0% |
| 2012 Q2 | -5.3 Million EUR | 0.0% |
| 2011 FY | -6.11 Million EUR | -9.86% |
| 2011 Q4 | -6.11 Million EUR | 0.0% |
| 2011 Q2 | -5.86 Million EUR | 0.0% |
| 2010 FY | -5.56 Million EUR | -21.77% |
| 2010 Q4 | -5.56 Million EUR | 0.0% |
| 2010 Q2 | -5.16 Million EUR | 0.0% |
| 2009 Q4 | -4.56 Million EUR | 0.0% |
| 2009 Q2 | -3.99 Million EUR | 0.0% |
| 2009 FY | -4.56 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 516.382% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 101.513% |
| Adocia SA | 127 Thousand EUR | -2240.92% |
| Aelis Farma SA | -16.19 Million EUR | 118.361% |
| Biophytis S.A. | 2.7 Million EUR | -9.988% |
| Advicenne S.A. | 12.17 Million EUR | 75.581% |
| IntegraGen SA | -709.74 Thousand EUR | 518.876% |
| Medesis Pharma S.A. | 1.15 Million EUR | -156.687% |
| Neovacs S.A. | -237.08 Thousand EUR | 1353.957% |
| NFL Biosciences SA | -2.27 Million EUR | 230.63% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 31.758% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 457.953% |
| Sensorion SA | 1.37 Million EUR | -115.71% |
| Theranexus Société Anonyme | 2.44 Million EUR | -21.636% |
| TME Pharma N.V. | -1.07 Million EUR | 375.53% |
| Valbiotis SA | -18.13 Million EUR | 116.39% |
| TheraVet SA | 12.78 Thousand EUR | -23153.571% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -36.375% |
| argenx SE | -1.83 Billion EUR | 100.162% |
| BioSenic S.A. | 28.04 Million EUR | 89.399% |
| Celyad Oncology SA | -6.1 Million EUR | 148.721% |
| DBV Technologies S.A. | -114.95 Million USD | 102.586% |
| Galapagos NV | -157.2 Million EUR | 101.891% |
| Genfit S.A. | -7.61 Million EUR | 139.061% |
| GeNeuro SA | 5.91 Million EUR | 49.699% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 111.839% |
| Innate Pharma S.A. | -30.71 Million EUR | 109.68% |
| Inventiva S.A. | 10.48 Million EUR | 71.656% |
| MaaT Pharma SA | -10.2 Million EUR | 129.132% |
| MedinCell S.A. | 39.5 Million EUR | 92.474% |
| Nanobiotix S.A. | -24.71 Million EUR | 112.028% |
| Onward Medical N.V. | -12.89 Million EUR | 123.057% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -107.851% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 89.041% |
| Oxurion NV | 10.71 Million EUR | 72.241% |
| Pharming Group N.V. | 99.4 Million EUR | 97.009% |
| Poxel S.A. | 44.55 Million EUR | 93.328% |
| GenSight Biologics S.A. | 16.29 Million EUR | 81.754% |
| Transgene SA | -14.4 Million EUR | 120.633% |
| Financière de Tubize SA | 78.62 Million EUR | 96.219% |
| UCB SA | 2.17 Billion EUR | 99.863% |
| Valneva SE | 82.73 Million EUR | 96.407% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 116.049% |